US 11,898,142 B2
Multi-effector CRISPR based diagnostic systems
Feng Zhang, Cambridge, MA (US); Jonathan Gootenberg, Cambridge, MA (US); and Omar Abudayyeh, Cambridge, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); and President and Fellows Harvard College, Cambridge, MA (US)
Appl. No. 16/645,571
Filed by THE BROAD INSTITUTE, INC., Cambridge, MA (US); MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
PCT Filed Sep. 7, 2018, PCT No. PCT/US2018/050091
§ 371(c)(1), (2) Date Mar. 9, 2020,
PCT Pub. No. WO2019/051318, PCT Pub. Date Mar. 14, 2019.
Claims priority of provisional application 62/630,808, filed on Feb. 14, 2018.
Claims priority of provisional application 62/610,121, filed on Dec. 22, 2017.
Claims priority of provisional application 62/556,408, filed on Sep. 9, 2017.
Prior Publication US 2020/0277600 A1, Sep. 3, 2020
Int. Cl. C12N 15/113 (2010.01); C12N 9/22 (2006.01); G01N 33/53 (2006.01); B01L 3/00 (2006.01)
CPC C12N 15/113 (2013.01) [B01L 3/5085 (2013.01); C12N 9/22 (2013.01); G01N 33/5308 (2013.01); B01L 2300/123 (2013.01); B01L 2300/126 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] 53 Claims
 
1. A nucleic acid detection system comprising:
a) a detection CRISPR system comprising:
i. a CRISPR effector protein having collateral cleavage activity,
ii. one or more guide RNAs designed to bind to corresponding target nucleic acids, and
iii. one or more signal amplification Type IIIa CRISPR effector proteins; and
b) one or more RNA-based masking constructs.